Table 2.
Prevalence of NAFLD and serum liver enzymes throughout the study in SCH patients.
| Variables | Significant SCH-LT4 (n = 33) |
Mild SCH patients | ||
|---|---|---|---|---|
| LT4 group (n = 181) |
Control group (n = 149) |
p value∗ | ||
| Prevalence of NAFLD, n (%) | ||||
| Baseline | 16 (48.5) | 80 (44.2) | 59 (39.6) | 0.400 |
| End-of-study | 8 (24.2) | 65 (35.9) | 52 (34.9) | 0.848 |
| p value# | 0.041 | 0.108 | 0.402 | — |
| ALT (IU/L) | ||||
| Baseline | 18.61 ± 7.67 | 19.09 ± 9.00 | 17.20 ± 8.35 | 0.050 |
| End-of-study | 17.15 ± 7.34 | 17.95 ± 7.71 | 17.29 ± 7.68 | 0.410 |
| p value# | 0.383 | 0.087 | 0.906 | — |
| Change in ALT | −1.46 ± 9.44 | −1.14 ± 8.77 | 0.09 ± 9.01 | 0.217 |
| AST (IU/L) | ||||
| Baseline | 26.12 ± 5.83 | 26.08 ± 6.80 | 24.65 ± 5.77 | 0.057 |
| End-of-study | 20.52 ± 6.69 | 21.22 ± 6.88 | 21.36 ± 6.48 | 0.854 |
| p value# | <0.001 | <0.001 | <0.001 | — |
| Change in AST | −5.61 ± 1.27 | −4.86 ± 7.34 | −3.29 ± 6.65 | 0.046 |
Values for quantitative data are expressed as mean ± standard deviation; values for categorical variables are expressed as number (percentage).
∗ p value for comparing variables between mild SCH-LT4 group and mild SCH-control group.
# p value for comparing variables between baseline and end-of-study within each group.
NAFLD: nonalcoholic fatty liver disease; SCH: subclinical hypothyroidism; LT4: levothyroxine; ALT: alanine aminotransferase; AST: aspartate aminotransferase.